Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.77% | 11.94% | -14.55% | -14.50% | -13.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.77% | 11.94% | -14.55% | -14.50% | -13.60% |
| Cost of Revenue | 34.73% | 2.59% | -42.76% | -53.34% | -53.72% |
| Gross Profit | 5.95% | 15.83% | 3.03% | 14.43% | 18.19% |
| SG&A Expenses | -11.43% | -8.87% | 3.31% | 5.91% | 7.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.44% | -18.75% | -15.99% | -14.03% | -10.78% |
| Operating Income | 45.32% | 48.43% | 17.91% | 13.46% | 7.59% |
| Income Before Tax | 39.18% | 26.35% | 18.66% | 2.63% | 10.67% |
| Income Tax Expenses | -107.79% | -107.79% | 25.53% | 25.53% | 25.53% |
| Earnings from Continuing Operations | 43.45% | 30.08% | 18.34% | 1.69% | 10.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.45% | 30.08% | 18.34% | 1.69% | 10.15% |
| EBIT | 45.32% | 48.43% | 17.91% | 13.46% | 7.59% |
| EBITDA | 47.77% | 51.09% | 19.85% | 15.73% | 10.04% |
| EPS Basic | 52.07% | 42.80% | 30.06% | 11.29% | 16.05% |
| Normalized Basic EPS | 48.68% | 40.01% | 27.82% | 10.88% | 14.90% |
| EPS Diluted | 52.07% | 42.80% | 30.06% | 11.29% | 16.05% |
| Normalized Diluted EPS | 48.68% | 40.01% | 27.82% | 10.88% | 14.90% |
| Average Basic Shares Outstanding | 18.39% | 22.00% | 19.38% | 14.14% | 8.54% |
| Average Diluted Shares Outstanding | 18.39% | 22.00% | 19.38% | 14.14% | 8.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |